Articles related to GUIDELINES/RECOMMENDATIONS

The American Academy of Sleep Medicine issued a health advisory on September 25, 2022, encouraging parents to seek medical advice before giving melatonin to children. Although melatonin can be useful in treating certain sleep-wake disorders like jet lag, there is much less evidence it can help healthy children or adults fall asleep faster. Symptoms of melatonin overdose can include headache, dizziness, and irritability.

A response to “practice-changing data” in the first- and second-line setting The American Society of Clinical Oncology (ASCO) has amended its advice against routinely administering PARP inhibitor monotherapy to patients with recurrent platinum-sensitive epithelial ovarian cancer in the second or later-line situation.

This update is based on the results from the June 2022 ATHENA-MONO2 phase III multinational, double-blind, randomized controlled trial (RCT), which showed a significant improvement in progression-free survival (PFS) in patients with stage III-IV epithelial ovarian cancer (EOC) who are in complete or partial response to first-line platinum-based chemotherapy.

Neurologic complications of COVID are leading to an increase in demand for both acute and long-term neurologic evaluation and management. Doctors Koralnik, Liotta, and Graham have been investigating the pathogenic mechanisms of acute and long-term COVID-19 and discuss here their guideline on managing neurologic complications of COVID.

The Sartor, et al randomized controlled trial (RCT), which demonstrated a significant improvement in radiographic progression-free survival and overall survival (OS) in patients with PSMA-positive mCRPC, served as the foundation for the 177Lutetium-PSMA-617 (177Lu-PSMA-617) March 2022 approval. The availability of this theranostic option served as a compelling argument for revising the 2014 proposal to include a prompt endorsement of 177Lu-PSMA-617. The mCRPC recommendations are now being updated completely.

Among doctors and researchers, the 2010 and 2017 versions of the European LeukemiaNet (ELN) recommendations for the diagnosis and treatment of acute myeloid leukemia (AML) in adults are broadly accepted. Researchers now have a better understanding of how AML develops from a molecular perspective, which has led to an update on the classification of the disease. Additionally, genomic diagnostics and the evaluation of measurable residual disease have advanced significantly, and new therapeutic agents like FLT3, IDH1, IDH2, and BCL2 inhibitors have been developed successfully. This update, which contains updated response criteria, therapy suggestions, and a revised ELN genetic risk classification, is a result of these developments.